Bonus Biogroup Stock Performance
| BBIXF Stock | USD 0.09 0.01 10.00% |
On a scale of 0 to 100, Bonus BioGroup holds a performance score of 4. The firm shows a Beta (market volatility) of 95.0, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Bonus BioGroup will likely underperform. Please check Bonus BioGroup's variance, skewness, as well as the relationship between the Skewness and day typical price , to make a quick decision on whether Bonus BioGroup's price patterns will revert.
Risk-Adjusted Performance
Soft
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Bonus BioGroup are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. Despite nearly uncertain basic indicators, Bonus BioGroup reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 16.1 M | |
| Total Cashflows From Investing Activities | -6.2 M |
Bonus |
Bonus BioGroup Relative Risk vs. Return Landscape
If you would invest 8.00 in Bonus BioGroup on November 4, 2025 and sell it today you would earn a total of 1.00 from holding Bonus BioGroup or generate 12.5% return on investment over 90 days. Bonus BioGroup is currently producing 0.8333% returns and takes up 13.597% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Bonus, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Bonus BioGroup Target Price Odds to finish over Current Price
The tendency of Bonus Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.09 | 90 days | 0.09 | about 16.52 |
Based on a normal probability distribution, the odds of Bonus BioGroup to move above the current price in 90 days from now is about 16.52 (This Bonus BioGroup probability density function shows the probability of Bonus Pink Sheet to fall within a particular range of prices over 90 days) .
Assuming the 90 days horizon the pink sheet has the beta coefficient of 95.0 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Bonus BioGroup will likely underperform. In addition to that Bonus BioGroup has an alpha of 399.9911, implying that it can generate a 399.99 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Bonus BioGroup Price Density |
| Price |
Predictive Modules for Bonus BioGroup
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Bonus BioGroup. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Bonus BioGroup's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Bonus BioGroup Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Bonus BioGroup is not an exception. The market had few large corrections towards the Bonus BioGroup's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Bonus BioGroup, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Bonus BioGroup within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 399.99 | |
β | Beta against Dow Jones | 95.00 | |
σ | Overall volatility | 0.01 | |
Ir | Information ratio | 0.12 |
Bonus BioGroup Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Bonus BioGroup for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Bonus BioGroup can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Bonus BioGroup is way too risky over 90 days horizon | |
| Bonus BioGroup has some characteristics of a very speculative penny stock | |
| Bonus BioGroup appears to be risky and price may revert if volatility continues | |
| Bonus BioGroup has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (90.08 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Bonus BioGroup generates negative cash flow from operations | |
| About 50.0% of the company shares are held by company insiders |
Bonus BioGroup Fundamentals Growth
Bonus Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Bonus BioGroup, and Bonus BioGroup fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Bonus Pink Sheet performance.
| Return On Equity | -0.55 | |||
| Return On Asset | -0.0636 | |||
| Current Valuation | 48.99 M | |||
| Shares Outstanding | 1.17 B | |||
| Price To Book | 4.05 X | |||
| EBITDA | (88.03 M) | |||
| Debt To Equity | 0.15 % | |||
| Cash Flow From Operations | (39.84 M) | |||
| Total Asset | 104.32 M | |||
About Bonus BioGroup Performance
By analyzing Bonus BioGroup's fundamental ratios, stakeholders can gain valuable insights into Bonus BioGroup's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Bonus BioGroup has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Bonus BioGroup has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Bonus BioGroup Ltd., a biotechnology company, develops technology solutions to generate tissue-regenerating bone grafts. Bonus BioGroup Ltd. was founded in 1981 and is based in Haifa, Israel. Bonus Biogroup is traded on OTC Exchange in the United States.Things to note about Bonus BioGroup performance evaluation
Checking the ongoing alerts about Bonus BioGroup for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Bonus BioGroup help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Bonus BioGroup is way too risky over 90 days horizon | |
| Bonus BioGroup has some characteristics of a very speculative penny stock | |
| Bonus BioGroup appears to be risky and price may revert if volatility continues | |
| Bonus BioGroup has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (90.08 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Bonus BioGroup generates negative cash flow from operations | |
| About 50.0% of the company shares are held by company insiders |
- Analyzing Bonus BioGroup's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Bonus BioGroup's stock is overvalued or undervalued compared to its peers.
- Examining Bonus BioGroup's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Bonus BioGroup's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Bonus BioGroup's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Bonus BioGroup's pink sheet. These opinions can provide insight into Bonus BioGroup's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Bonus Pink Sheet analysis
When running Bonus BioGroup's price analysis, check to measure Bonus BioGroup's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bonus BioGroup is operating at the current time. Most of Bonus BioGroup's value examination focuses on studying past and present price action to predict the probability of Bonus BioGroup's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bonus BioGroup's price. Additionally, you may evaluate how the addition of Bonus BioGroup to your portfolios can decrease your overall portfolio volatility.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |